Zentalis Pharmaceuticals

ZNTL

Biotechnology · Healthcare

Price

$3.83

-0.01 (-0.39%)

Market Cap

$272.3M

Exchange

NASDAQ

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Share count rising — dilution

+68.4% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 42.7M (2021) → 71.9M (2025)

Winston Score History

The full picture

Zentalis Pharmaceuticals is a clinical-stage biotech company that discovers and develops cancer drugs. Its main focus is on a class of medicines called BCL-2 inhibitors, which work by triggering cancer cells to self-destruct. The company's lead drug candidate, azenosertib, targets a protein called WEE1 and is being tested in patients with various solid tumors.

Zentalis makes no product revenue yet because its drugs are still in clinical trials. The company is based in the United States and funds its operations through equity raises and partnerships, which is typical for early-stage biotechs. With a negative ROIC of over 65%, it is burning through cash to advance its pipeline. The biggest risk is that clinical trials could fail, which would severely damage the company's value, while success in late-stage trials and eventual FDA approval remain the primary catalysts for future growth.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

YoY Growth Rate

Revenue data limited

EPS Growth

-197.3% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$107M/ year

↓ Declining (-36% vs prior year)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

31.8%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~8 months

$177M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Cash watch

Zentalis Pharmaceuticals has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

Data not available

Profit after running costs

Operating Margin

N/A

Data not available

Return on the money invested

ROCE

-129.4%

Weak — -129.4% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

-100.0%

Shrinking sales (-100.0% YoY)

Profit growth

EPS YoY

N/A

Data not available

How steady the profit is

EPS Consistency

6/8 quarters

Earnings grew in most of the last 8 quarters

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.03

Conservative — low debt load (0.03)

Covers its interest

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial